MEDSIR announces positive results from TUXEDO-3 trial of patritumab deruxtecan in patients with active brain metastases and leptomeningeal disease: Chicago Monday, June 9, 2025, 1 ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and ...